---
title: "ICCM: First FDA-cleared minimally invasive cryoablation device for breast cancer, driving global growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292679809.md"
description: "ProSense is the only FDA-authorized minimally invasive cryoablation device for breast cancer, offering rapid recovery, superior cosmetic outcomes, and strong clinical validation. With global regulatory approvals, robust IP, and strategic partnerships, the platform is poised for significant growth and expansion into additional cancer indications.Original document: IceCure Medical Ltd. [ICCM] Slides Release — Jul. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-14T21:57:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292679809.md)
  - [en](https://longbridge.com/en/news/292679809.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292679809.md)
---

# ICCM: First FDA-cleared minimally invasive cryoablation device for breast cancer, driving global growth

ProSense is the only FDA-authorized minimally invasive cryoablation device for breast cancer, offering rapid recovery, superior cosmetic outcomes, and strong clinical validation. With global regulatory approvals, robust IP, and strategic partnerships, the platform is poised for significant growth and expansion into additional cancer indications.

Original document: IceCure Medical Ltd. \[ICCM\] Slides Release — Jul. 14 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ICCM.US](https://longbridge.com/en/quote/ICCM.US.md)

## Related News & Research

- [IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site | ICCM Stock News](https://longbridge.com/en/news/293933610.md)
- [IceCure Medical publishes investor presentation on ProSense FDA-cleared cryoablation treatment for low-risk breast cancer](https://longbridge.com/en/news/292404676.md)
- [Regulatory and Legal Risks: How Emerging AI Laws and IP Rules Threaten Bandwidth’s Operations and Reputation](https://longbridge.com/en/news/294315070.md)
- [KTTA: PAS-004 shows strong safety, efficacy, and market potential for NF1 and solid tumors](https://longbridge.com/en/news/294267795.md)
- [Capgemini sees multi-year IT modernisation boom as firms prepare for AI](https://longbridge.com/en/news/294321168.md)